This prospective, multi-center, observational study will assess the efficacy and safety of treatment in patients who are treated with a TNF Inhibitor or RoActemra/Actemra (tocilizumab) as the first biologic therapy. Data will be collected for 52 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01543503?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
